SCM Life Sciences Applies for IND for Domestic Phase 2a Clinical Trial of Respiratory Distress Syndrome 'SCM-AGH'
[Asia Economy Reporter Minji Lee] SCM Life Sciences announced on the 11th that it has submitted an Investigational New Drug (IND) application for the Phase 2a clinical trial of 'SCM-AGH' for patients with moderate to severe acute respiratory distress syndrome to the Ministry of Food and Drug Safety.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
- Seoul Apartment Sales, Jeonse, and Rents in 'Triple Bull Run'... Worst Supply Shortage in 5 Years
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
The company explained, “SCM-AGH is expected to be effective in treating acute respiratory distress syndrome, a disease characterized by excessive inflammatory responses, by inhibiting the production of pro-inflammatory cytokines and increasing the production of anti-inflammatory cytokines.”
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
